ASCO Genitourinary Symposium

Keytruda Plus Cabometyx Produces Responses in Cisplatin-Ineligible Bladder Cancer

January 27th 2024, 6:00pm

Article

Frontline treatment with Keytruda and Cabometyx produced responses with a manageable safety profile in patients with cisplatin-ineligible urothelial carcinoma, a type of bladder cancer.

Nubeqa, Hormone Therapy May Reduce Hospitalizations in Prostate Cancer

January 27th 2024, 2:00pm

Article

Nubeqa plus androgen deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer lowered hospitalization rates but led to marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy and docetaxel.

Keytruda Side Effects: ‘If Something Doesn’t Feel Right … Call’

January 26th 2024, 11:00pm

Video

Patients with bladder cancer being treated with the immunotherapy agent, Keytruda, should not hesitate to call their oncology team if something does not feel right, an expert said.

Many Patients Miss Out on Testing to Guide Prostate Cancer Treatment

January 26th 2024, 10:00pm

Article

Approximately 40% of patients with metastatic castration-resistant prostate cancer did not undergo certain types of tests that can be instrumental in treatment decisions.

Prostate Cancer Outcomes Improve With Zytiga, Prednisone, Erleada

January 26th 2024, 8:00pm

Article

Treatment with Zytiga, prednisone and Erleada plus another treatment regimen improved prostate cancer outcomes and did not change health-related quality of life outcomes.

Lynparza Plus Zytiga Boosts PFS, Response Rates in Metastatic Prostate Cancer

January 26th 2024, 2:00pm

Article

Lynparza, Zytiga and prednisone led to improved progression-free survival and response rates in patients with metastatic prostate cancer.

Cabometyx, Tecentriq Combo Improves Time to Progression in mCRPC

January 25th 2024, 10:00pm

Article

Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.

An Expert Discusses Nubeqa Side Effects Patients Should Know About

March 2nd 2023, 10:00pm

Video

Long-term follow-up of Nubeqa for nonmetastatic castration-resistant prostate cancer showed that the drug was safe and effective in treating this patient population.

3 Important Patient-Provider Discussions for Newly Diagnosed Kidney Cancer

February 27th 2023, 4:01pm

Video

After a patient receives a kidney cancer diagnosis, there are some important conversations to have with their health care team.

What to Expect During Genomic Testing for Prostate Cancer

February 22nd 2023, 4:00pm

Video

An expert explains what patients with low-grade prostate cancer can expect when undergoing genomic testing — and why the procedure is important.